Qiagen NV
Qiagen NV develops sample and assay technologies to enable molecular testing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Qiagen's stock with a target price of $50.65, indicating growth potential.
Financial Health
Qiagen is performing well with strong profits and cash flow, indicating good business health.
Dividend
Qiagen's projected dividend yield of 0.03% is low, indicating limited returns for dividend-seeking investors. If you invested $1000 you would be paid $0.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring QGEN
Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Qiagen earns steady revenue from consumables and reagents that labs repurchase regularly, though sales can fluctuate with testing demand.
Global Diagnostics Reach
A broad international footprint gives exposure to varied markets and growth opportunities, but also brings foreign‑exchange and regional regulatory risks.
Oncology & Precision Medicine
Growth in companion diagnostics and personalised therapies could be a catalyst, while competition and reimbursement remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
